The new fluoroquinolone antibiotics

Clinical Microbiology Newsletter

Volumn 20, Issue 24, 1998, Pages 197-201

  Bonomo, Robert A ^a  

^a UNIVERSITY HOSPITALS OF CLEVELAND   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 0001579950     PISSN: 01964399     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0196-4399(00)88669-9     Document Type: Article

References (26)

1. Stein, G.E. 1996. Pharmacokinetics and pharmacodynamics of newer fluoroquinolones. Clin. Infect. Dis. 23(Suppl 1): S19-24.
2. Nicolau, D.P. 1998. Fluoroquinolone pharmacokinetics, pharmacodynamics and drug interactions. Formulary 33(Suppl. 3):S27-S33.
3. Brightly, K.E., and T.D. Gootz. 1997. The chemistry and biological profile of trovafloxacin. J. Antimicrob. Chemother. 39(Suppl B):1-14.
4. Shen, L.L. and A.G. Pernet. 1985. Mechanism of inhibition of DNA gyrase by analogues of nalidixic acid: the target of the drugs is DNA. Proc. Natl. Acad. Sci. (USA) 82:307-311.
5. Garcia, I. et al. 1992. Uptake and intracellular activity of sparfloxacin in human polymorphonuclear leukocytes and tissue culture cells. Antimicrob. Agents Chemother. 36:1053-1056.
6. Lianou, P.E. et al. 1993. In vivo potientation of polymorphonuclear leukocyte function by ciprofloxacin. J. Chemother. 1993 5:223-227.
7. Wiedemann, B. and P. Heisig. 1994. Mechanism of quinolone resistance. Infection 22(Suppl. 2): S73-S79.
8. Blumberg, H.M. and D. Rimland. 1995. Ciprofloxacin resistance among nosocomial Pseudomonas aeruginosa and Staphylococcus aureus in the United States. Infect. Control Hosp. Epidemiol. 16:620-621.
9. Coronado, V.G. et al. 1995. Ciprofloxacin resistance among nosocomial Pseudomonas aeruginosa and Staphylococcus aureus in the United States. National Nosocomial Infections Surveillance (NNIS) System. Infect. Control Hosp. Epidemiol. 16:71-75.
10. Knapp, J.S. et al. 1997. Fluoroquinolone resistance in Neisseria gonorrheae. Emerging Infect. Dis. 3:33-39.
11. Fox, K.K. et al. 1997. Antimicrobial resistance in Neisseria gonorrheae in the United States, 1988-1994; The emergence of decreased susceptibility to fluoroquinolones. J. Infect. Dis. 175:1396-1403.
12. Goa, K.L., H.M. Bryson, and A. Markham. 1997. Sparfloxacin. A review of its antibacterial activity, pharmacokinetic properties, clinical efficacy and tolerability in lower respiratory tract infections. Drugs 53:700-725.
13. Visalli, M.A. et al. 1997. Comparative activity of trovafloxacin, alone and in combination with other agents, against gram-negative nonfermentative rods. Antimicrob. Agents Chemother. 41:1475-1481.
14. Bauernfeind, A. 1997. Comparison of the antibacterial activities of the quinolones Bay 12-8039, gatifloxacin (AM 1155), trovafloxacin, clinafloxacin, levofloxacin and ciprofloxacin. J. Antimicrob. Chemother. 40:639-651.
15. Haria, M. and H.M. Lamb. 1997. Trovafloxacin. Drugs. 54:435-445.
16. Cohen, M.A. et al. 1997. In-vitro activity of clinafloxacin, trovafloxacin, and ciprofloxacin. J. Antimicrob. Chemother. 40:205-211.
17. Spangler, S.K., M.R. Jacobs, and P.C. Applebaum. 1996. Susceptibility of anaerobic bacteria to trovafloxacin. Comparison with quinolones and nonquinolone antibiotics. Infectious Diseases in Clinical Practice 5(Suppl): S101-S109.
18. Goldstein, G.J.C. 1996. Possible role of the new fluoroquinolones (levofloxacin, grepafloxacin, trovafloxacin, clinafloxacin, sparfloxacin and Du-6859a) in the treatment of anaerobic infections:a review of current information on efficacy and safety. Clin. Infect. Dis. 23(Suppl 10):S25-S30.
19. Martin, S.J. et al. 1998. Levofloxacin and sparfloxacin: new quinolone antibiotics. Ann. Pharmacother. 32:320-336.
20. File, T.M. et al. 1997. A multicenter, randomized study comparing the efficacy and safety of intravenous and/or oral levofloxacin versus ceftriaxone and/or cefuroxime axetil in treatment of adults with community-acquired pneumonia. Antimicrob. Agents Chemother. 41:1965-1972.
21. Wagstaff, A.J. and J.A. Balfour. 1997. Grepafloxacin. Drugs 53:817-820.
22. Wiedemann, B. and P. Heisig. 1997. Antibacterial activity of grepafloxacin. J. Antimicrob. Chemother. 40(Suppl A): 19-25.
23. Fuchs, P.C., A.L. Barry, and S.D. Brown. 1998. In vitro activities of clinofloxacin against contemporary clinical bacterial isolates from 10 North American centers. Antimicrob. Agents Chemother. 42:1274-1277.
24. Ednie, L.M., M.R. Jacobs, and P.C. Appelbaum. 1998. Comparative activities of clinofloxacin against gram-positive and negative bacteria. Antimicrob. Agents Chemother. 42:1269-1273.
25. Fish, D.N. and A.T. Chow. 1997. The clinical pharmacokinetics of levofloxacin. Clin. Pharmacokinetics 32:101-119.
26. National Committee for Clinical Laboratory Standards. 1998. Performance Standards for Antimicrobial Susceptibility Testing; Eighth Informational Supplement. M100 S8. NCCLS. Wayne, PA.